ETFOptimize | High-performance ETF-based Investment Strategies

Quantitative strategies, Wall Street-caliber research, and insightful market analysis since 1998.


ETFOptimize | HOME
Close Window

The Dow Jones Looks Ready for Death, But These 3 Blue-Chip Stocks Have More Life (and Gains) Ahead

Every trader has their favorite setups, angles and go-to’s. One of mine is, for lack of a better expression, the “counter trade.” As I define it, I take an index exchange-traded fund (ETF) that looks dreadful to me technically. Then, I try to find some stocks within it which look promising for gains. 

My objective is typically to buy an inverse ETF or put option on the index, while buying the stocks within that index which have the best shot to produce gains. My time horizon is weeks, maybe months. And while it is not always easy to find those standouts, when I do, it is well worth it.

 

The broad stock market looks ill to me. Maybe something will turn that around quickly. But I’m not counting on it. In particular, the Dow Jones Industrial Average ($DOWI) and the Dow Jones Industrials SPDR (DIA) ETF look especially vulnerable to me. That doesn’t mean gains are not possible, only that risk is high.

So my mission, apart from looking at possibly buying an ETF that runs counter to DIA, or buying a put option on it, is to see where the outliers are. That is, the stocks within that tidy 30-member index that might be upside leaders anyway. Even if they simply outperform in a down market, there’s “alpha” and positive return to be had. In a treacherous market like this one, why not look around every corner, and under every rock? I try to.

So with that as the task, here are three Dow Industrials components that I picked out of the 30 in that venerable index. They all have at least a fighting chance to earn a profitable return over the balance of 2025. Here they are.

www.barchart.com

Stock #1: Merck 

Merck (MRK) has the best-looking chart in the Dow 30 by far. And it’s about time! It has been languishing amid a range of issues, some related to drug pricing regulation, some to the company’s own maladies. But this is still a blue-chip healthcare firm. And the weekly chart shows promise. An earnings multiple under 11x adds to the attraction here. 

www.barchart.com

Stock #2: 3M 

3M (MMM) has quietly had an outstanding run. And while it is far from undervalued technically, it is a rock-solid blue-chip, if not the most dynamic. 21x earnings is not a steal, but these are times when simply avoiding terrible chart patterns might end up looking like a “win.” The Percentage Price Oscillator (PPO) here is hinting at another leg higher, and MMM is making up for some lost time here. 

www.barchart.com

Stock #3: Chevron 

www.barchart.com

Chevron (CVX) is a good example of the fact that at times like these, a range-bound chart coupled with a price-sales ratio under 2x is a good combination. There’s a nice 4.5% dividend yield here too.

These three stocks all have upside potential. But just as importantly, their charts and valuations are not as risky looking to me as most tech stocks. That alone could be a ticket to success the remainder of this year.


On the date of publication, Rob Isbitts did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.

 

More news from Barchart

Recent Quotes

View More
Symbol Price Change (%)
AMZN  220.69
+3.55 (1.63%)
AAPL  271.49
+5.24 (1.97%)
AMD  203.78
-2.24 (-1.09%)
BAC  51.56
+0.56 (1.10%)
GOOG  299.65
+9.67 (3.33%)
META  594.25
+5.10 (0.87%)
MSFT  472.12
-6.31 (-1.32%)
NVDA  178.88
-1.76 (-0.97%)
ORCL  198.76
-11.93 (-5.66%)
TSLA  391.09
-4.14 (-1.05%)
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.


 

IntelligentValue Home
Close Window

DISCLAIMER

All content herein is issued solely for informational purposes and is not to be construed as an offer to sell or the solicitation of an offer to buy, nor should it be interpreted as a recommendation to buy, hold or sell (short or otherwise) any security.  All opinions, analyses, and information included herein are based on sources believed to be reliable, but no representation or warranty of any kind, expressed or implied, is made including but not limited to any representation or warranty concerning accuracy, completeness, correctness, timeliness or appropriateness. We undertake no obligation to update such opinions, analysis or information. You should independently verify all information contained on this website. Some information is based on analysis of past performance or hypothetical performance results, which have inherent limitations. We make no representation that any particular equity or strategy will or is likely to achieve profits or losses similar to those shown. Shareholders, employees, writers, contractors, and affiliates associated with ETFOptimize.com may have ownership positions in the securities that are mentioned. If you are not sure if ETFs, algorithmic investing, or a particular investment is right for you, you are urged to consult with a Registered Investment Advisor (RIA). Neither this website nor anyone associated with producing its content are Registered Investment Advisors, and no attempt is made herein to substitute for personalized, professional investment advice. Neither ETFOptimize.com, Global Alpha Investments, Inc., nor its employees, service providers, associates, or affiliates are responsible for any investment losses you may incur as a result of using the information provided herein. Remember that past investment returns may not be indicative of future returns.

Copyright © 1998-2017 ETFOptimize.com, a publication of Optimized Investments, Inc. All rights reserved.